I agree that this site is using cookies. You can find further informations
here
.
X
Login
My folder (
0
)
Home
About us
Home About us
Our history
Profile
Press & public relations
Friends
The library in figures
Exhibitions
Projects
Training, internships, careers
Films
Services & Information
Home Services & Information
Lending and interlibrary loans
Returns and renewals
Training and library tours
My Account
Library cards
New to the library?
Download Information
Opening hours
Learning spaces
PC, WLAN, copy, scan and print
Catalogs and collections
Home Catalogs and Collections
Rare books and manuscripts
Digital collections
Subject Areas
Our sites
Home Our sites
Central Library
Law Library (Juridicum)
BB Business and Economics (BB11)
BB Physics and Electrical Engineering
TB Engineering and Social Sciences
TB Economics and Nautical Sciences
TB Music
TB Art & Design
TB Bremerhaven
Contact the library
Home Contact the library
Staff Directory
Open access & publishing
Home Open access & publishing
Reference management: Citavi & RefWorks
Publishing documents
Open Access in Bremen
Show Desktop-Version
Toggle navigation
Anguille, S
42
results:
Search for persons
X
Format
Online (42)
Mediatypes
Articles (Online) (20)
OpenAccess-fulltext (22)
Sorted by: Relevance
Sorted by: Year
?
1
B09 CARTITUDE-2 COHORT B 18-MONTH FOLLOW-UP: CILTACABTAGENE..:
Zweegman, S.
;
Agha, M.
;
Cohen, A.D.
...
HemaSphere. 7 (2023) S2 - p. 8-8 , 2023
Link:
https://doi.org/10.1097/..
?
2
P30 SINGLE COHORT RESULTS FROM MAJESTEC-2: TECLISTAMAB (TEC..:
Searle, E.
;
Quach, H.
;
Wong, S.
...
HemaSphere. 7 (2023) S2 - p. 27-27 , 2023
Link:
https://doi.org/10.1097/..
?
3
B07: SAFETY AND EFFICACY OF CILTACABTAGENE AUTOLEUCEL, A CH..:
van de Donk, NWCJ
;
Delforge, M
;
Agha, M
...
HemaSphere. 6 (2022) - p. 9-10 , 2022
Link:
https://doi.org/10.1097/..
?
4
Comparison of S1 antibody titers between BNT162b2 and ChAdO..:
van Dam, P.A.
;
Debie, Y.
;
Teuwen, L.
...
ESMO Open. 7 (2022) 2 - p. 100414 , 2022
Link:
https://doi.org/10.1016/..
?
5
S185: CARTITUDE-2 COHORT B: UPDATED CLINICAL DATA AND BIOLO..:
Agha, M. E.
;
van de Donk, N. W.
;
Cohen, A. D.
...
HemaSphere. 6 (2022) - p. 86-87 , 2022
Link:
https://doi.org/10.1097/..
?
6
PB2348: THE PATIENT'S PERSPECTIVE ON CLNICAL TRIALS: RESULT..:
Heyrman, B.
;
Meers, S.
;
Van De Velde, A.
.
HemaSphere. 6 (2022) - p. 2217-2218 , 2022
Link:
https://doi.org/10.1097/..
?
7
P12: TREATMENTS IN PATIENTS WITH RELAPSED/REFRACTORY MULTIP..:
Vekemans, M-C
;
Delforge, M
;
Anguille, S
...
HemaSphere. 6 (2022) - p. 17-18 , 2022
Link:
https://doi.org/10.1097/..
?
8
Reduced humoral immune response after BNT162b2 coronavirus ..:
Peeters, M.
;
Verbruggen, L.
;
Teuwen, L.
...
ESMO Open. 6 (2021) 5 - p. 100274 , 2021
Link:
https://doi.org/10.1016/..
?
9
Vaccination of cancer patients with dendritic cells electro..:
Berneman, Z.N.
;
Anguille, S.
;
Willemen, Y.
...
Cytotherapy. 21 (2019) 5 - p. S10 , 2019
Link:
https://doi.org/10.1016/..
?
10
mRNA Loaded CMRF-56 Blood Dendritic Cells Augment Anti-Canc..:
Papadimitrious, M.
;
Fromm, P.D.
;
Van Kooten Losio, N.
...
Cytotherapy. 18 (2016) 6 - p. S100 , 2016
Link:
https://doi.org/10.1016/..
?
11
Medical costs of treatment and survival of patients with ac..:
Van de Velde, A.L.
;
Beutels, P.
;
Smits, E.L.
...
Leukemia Research. 46 (2016) - p. 26-29 , 2016
Link:
https://doi.org/10.1016/..
?
12
Vaccination with Wilms' Tumor Antigen (WT1) mRNA-Electropor..:
Berneman, Z.
;
Van de Velde, A.
;
Anguille, S.
...
Cytotherapy. 18 (2016) 6 - p. S13-S14 , 2016
Link:
https://doi.org/10.1016/..
?
13
Anti-cancer vaccination using mRNA-loaded CMRF-56 immunosel..:
Fromm, P.D.
;
Anguille, S.
;
Papadimitrious, M.
...
Cytotherapy. 16 (2014) 4 - p. S24 , 2014
Link:
https://doi.org/10.1016/..
?
14
Generation of killer dendritic cells starting from blood mo..:
Anguille, S.
;
Lion, E.
;
Tel, J.
...
Cytotherapy. 15 (2013) 4 - p. S34 , 2013
Link:
https://doi.org/10.1016/..
?
15
mRNA loading of human blood dendritic cells for anti-cancer..:
Fromm, P.D.
;
Anguille, S.
;
Hart, D.N.
Cytotherapy. 15 (2013) 4 - p. S35 , 2013
Link:
https://doi.org/10.1016/..
1-15